The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Immuno-oncology Drugs-Global Market Insights and Sales Trends 2025
Synopsis
Immunotherapy is treatment that uses a certain part of a person’s immune system to fight diseases which is done by stimulating one’s own immune system to work harder to attack cancer cells or by giving immune system components, such as man-made immune system proteins. Immunotherapy includes treatments that work in different ways. Some boost the body’s immune system in a very general way and others help train the immune system to attack cancer cells specifically.
The global Immuno-oncology Drugs market size is expected to reach US$ 51870 million by 2029, growing at a CAGR of 16.8% from 2023 to 2029. The market is mainly driven by the significant applications of Immuno-oncology Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Ambulatory Surgical Centers,, are propelling Immuno-oncology Drugs market. Immune Checkpoint Inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Immune System Modulators segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Immuno-oncology Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Immuno-oncology Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Immuno-oncology Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Immuno-oncology Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Immuno-oncology Drugs covered in this report include Amgen, Inc, AstraZeneca, Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., Hoffmann-La Roche AG, Johnson & Johnson and Novartis International AG, etc.
The global Immuno-oncology Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Amgen, Inc
AstraZeneca, Plc
Bristol-Myers Squibb
Celgene Corporation
Eli Lilly and Company
Merck & Co.
Hoffmann-La Roche AG
Johnson & Johnson
Novartis International AG
AbbVie, Inc.
Pfizer Inc.
Sanofi S.A.
EMD Serono, Inc.
Gilead Sciences Inc.
Prometheus Therapeutics & Diagnostics
Aduro BioTech
Galena Biopharma
Bavarian Nordic
Celldex Therapeutics
ImmunoCellular Therapeutics
Incyte
Dendreon Corporation
Agilent Technologies Inc.
Agenus Inc.
Enzo Biochem, Inc.
Lonza Group
Bio-Rad Laboratories, Inc.
Avantor, Inc.
Spring Bank Pharmaceuticals, Inc.
Ferring Pharmaceuticals
Global Immuno-oncology Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Immuno-oncology Drugs market, Segment by Type:
Immune Checkpoint Inhibitors
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
Global Immuno-oncology Drugs market, by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Immuno-oncology Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Immunotherapy is treatment that uses a certain part of a person’s immune system to fight diseases which is done by stimulating one’s own immune system to work harder to attack cancer cells or by giving immune system components, such as man-made immune system proteins. Immunotherapy includes treatments that work in different ways. Some boost the body’s immune system in a very general way and others help train the immune system to attack cancer cells specifically.
The global Immuno-oncology Drugs market size is expected to reach US$ 51870 million by 2029, growing at a CAGR of 16.8% from 2023 to 2029. The market is mainly driven by the significant applications of Immuno-oncology Drugs in various end use industries. The expanding demands from the Hospitals, Clinics and Ambulatory Surgical Centers,, are propelling Immuno-oncology Drugs market. Immune Checkpoint Inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Immune System Modulators segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Immuno-oncology Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Immuno-oncology Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Immuno-oncology Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Immuno-oncology Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Immuno-oncology Drugs covered in this report include Amgen, Inc, AstraZeneca, Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., Hoffmann-La Roche AG, Johnson & Johnson and Novartis International AG, etc.
The global Immuno-oncology Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Amgen, Inc
AstraZeneca, Plc
Bristol-Myers Squibb
Celgene Corporation
Eli Lilly and Company
Merck & Co.
Hoffmann-La Roche AG
Johnson & Johnson
Novartis International AG
AbbVie, Inc.
Pfizer Inc.
Sanofi S.A.
EMD Serono, Inc.
Gilead Sciences Inc.
Prometheus Therapeutics & Diagnostics
Aduro BioTech
Galena Biopharma
Bavarian Nordic
Celldex Therapeutics
ImmunoCellular Therapeutics
Incyte
Dendreon Corporation
Agilent Technologies Inc.
Agenus Inc.
Enzo Biochem, Inc.
Lonza Group
Bio-Rad Laboratories, Inc.
Avantor, Inc.
Spring Bank Pharmaceuticals, Inc.
Ferring Pharmaceuticals
Global Immuno-oncology Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Immuno-oncology Drugs market, Segment by Type:
Immune Checkpoint Inhibitors
Immune System Modulators
Cancer Vaccines
Oncolytic Virus
Others
Global Immuno-oncology Drugs market, by Application
Hospitals
Clinics
Ambulatory Surgical Centers
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Immuno-oncology Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Immuno-oncology Drugs
1.1 Immuno-oncology Drugs Market Overview
1.1.1 Immuno-oncology Drugs Product Scope
1.1.2 Immuno-oncology Drugs Market Status and Outlook
1.2 Global Immuno-oncology Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Immuno-oncology Drugs Market Size by Region (2018-2029)
1.4 Global Immuno-oncology Drugs Historic Market Size by Region (2018-2023)
1.5 Global Immuno-oncology Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Immuno-oncology Drugs Market Size (2018-2029)
1.6.1 North America Immuno-oncology Drugs Market Size (2018-2029)
1.6.2 Europe Immuno-oncology Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Immuno-oncology Drugs Market Size (2018-2029)
1.6.4 Latin America Immuno-oncology Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Immuno-oncology Drugs Market Size (2018-2029)
2 Immuno-oncology Drugs Market by Type
2.1 Introduction
2.1.1 Immune Checkpoint Inhibitors
2.1.2 Immune System Modulators
2.1.3 Cancer Vaccines
2.1.4 Oncolytic Virus
2.1.5 Others
2.2 Global Immuno-oncology Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Immuno-oncology Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Immuno-oncology Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Immuno-oncology Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Immuno-oncology Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Immuno-oncology Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Immuno-oncology Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Immuno-oncology Drugs Revenue Breakdown by Type (2018-2029)
3 Immuno-oncology Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Ambulatory Surgical Centers
3.2 Global Immuno-oncology Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Immuno-oncology Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Immuno-oncology Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Immuno-oncology Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Immuno-oncology Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Immuno-oncology Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Immuno-oncology Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Immuno-oncology Drugs Revenue Breakdown by Application (2018-2029)
4 Immuno-oncology Drugs Competition Analysis by Players
4.1 Global Immuno-oncology Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Immuno-oncology Drugs as of 2022)
4.3 Date of Key Players Enter into Immuno-oncology Drugs Market
4.4 Global Top Players Immuno-oncology Drugs Headquarters and Area Served
4.5 Key Players Immuno-oncology Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Immuno-oncology Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Amgen, Inc
5.1.1 Amgen, Inc Profile
5.1.2 Amgen, Inc Main Business
5.1.3 Amgen, Inc Immuno-oncology Drugs Products, Services and Solutions
5.1.4 Amgen, Inc Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Amgen, Inc Recent Developments
5.2 AstraZeneca, Plc
5.2.1 AstraZeneca, Plc Profile
5.2.2 AstraZeneca, Plc Main Business
5.2.3 AstraZeneca, Plc Immuno-oncology Drugs Products, Services and Solutions
5.2.4 AstraZeneca, Plc Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 AstraZeneca, Plc Recent Developments
5.3 Bristol-Myers Squibb
5.3.1 Bristol-Myers Squibb Profile
5.3.2 Bristol-Myers Squibb Main Business
5.3.3 Bristol-Myers Squibb Immuno-oncology Drugs Products, Services and Solutions
5.3.4 Bristol-Myers Squibb Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Celgene Corporation Recent Developments
5.4 Celgene Corporation
5.4.1 Celgene Corporation Profile
5.4.2 Celgene Corporation Main Business
5.4.3 Celgene Corporation Immuno-oncology Drugs Products, Services and Solutions
5.4.4 Celgene Corporation Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Celgene Corporation Recent Developments
5.5 Eli Lilly and Company
5.5.1 Eli Lilly and Company Profile
5.5.2 Eli Lilly and Company Main Business
5.5.3 Eli Lilly and Company Immuno-oncology Drugs Products, Services and Solutions
5.5.4 Eli Lilly and Company Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Eli Lilly and Company Recent Developments
5.6 Merck & Co.
5.6.1 Merck & Co. Profile
5.6.2 Merck & Co. Main Business
5.6.3 Merck & Co. Immuno-oncology Drugs Products, Services and Solutions
5.6.4 Merck & Co. Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Merck & Co. Recent Developments
5.7 Hoffmann-La Roche AG
5.7.1 Hoffmann-La Roche AG Profile
5.7.2 Hoffmann-La Roche AG Main Business
5.7.3 Hoffmann-La Roche AG Immuno-oncology Drugs Products, Services and Solutions
5.7.4 Hoffmann-La Roche AG Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Hoffmann-La Roche AG Recent Developments
5.8 Johnson & Johnson
5.8.1 Johnson & Johnson Profile
5.8.2 Johnson & Johnson Main Business
5.8.3 Johnson & Johnson Immuno-oncology Drugs Products, Services and Solutions
5.8.4 Johnson & Johnson Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Johnson & Johnson Recent Developments
5.9 Novartis International AG
5.9.1 Novartis International AG Profile
5.9.2 Novartis International AG Main Business
5.9.3 Novartis International AG Immuno-oncology Drugs Products, Services and Solutions
5.9.4 Novartis International AG Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Novartis International AG Recent Developments
5.10 AbbVie, Inc.
5.10.1 AbbVie, Inc. Profile
5.10.2 AbbVie, Inc. Main Business
5.10.3 AbbVie, Inc. Immuno-oncology Drugs Products, Services and Solutions
5.10.4 AbbVie, Inc. Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.10.5 AbbVie, Inc. Recent Developments
5.11 Pfizer Inc.
5.11.1 Pfizer Inc. Profile
5.11.2 Pfizer Inc. Main Business
5.11.3 Pfizer Inc. Immuno-oncology Drugs Products, Services and Solutions
5.11.4 Pfizer Inc. Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.11.5 Pfizer Inc. Recent Developments
5.12 Sanofi S.A.
5.12.1 Sanofi S.A. Profile
5.12.2 Sanofi S.A. Main Business
5.12.3 Sanofi S.A. Immuno-oncology Drugs Products, Services and Solutions
5.12.4 Sanofi S.A. Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.12.5 Sanofi S.A. Recent Developments
5.13 EMD Serono, Inc.
5.13.1 EMD Serono, Inc. Profile
5.13.2 EMD Serono, Inc. Main Business
5.13.3 EMD Serono, Inc. Immuno-oncology Drugs Products, Services and Solutions
5.13.4 EMD Serono, Inc. Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.13.5 EMD Serono, Inc. Recent Developments
5.14 Gilead Sciences Inc.
5.14.1 Gilead Sciences Inc. Profile
5.14.2 Gilead Sciences Inc. Main Business
5.14.3 Gilead Sciences Inc. Immuno-oncology Drugs Products, Services and Solutions
5.14.4 Gilead Sciences Inc. Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.14.5 Gilead Sciences Inc. Recent Developments
5.15 Prometheus Therapeutics & Diagnostics
5.15.1 Prometheus Therapeutics & Diagnostics Profile
5.15.2 Prometheus Therapeutics & Diagnostics Main Business
5.15.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Products, Services and Solutions
5.15.4 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.15.5 Prometheus Therapeutics & Diagnostics Recent Developments
5.16 Aduro BioTech
5.16.1 Aduro BioTech Profile
5.16.2 Aduro BioTech Main Business
5.16.3 Aduro BioTech Immuno-oncology Drugs Products, Services and Solutions
5.16.4 Aduro BioTech Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.16.5 Aduro BioTech Recent Developments
5.17 Galena Biopharma
5.17.1 Galena Biopharma Profile
5.17.2 Galena Biopharma Main Business
5.17.3 Galena Biopharma Immuno-oncology Drugs Products, Services and Solutions
5.17.4 Galena Biopharma Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.17.5 Galena Biopharma Recent Developments
5.18 Bavarian Nordic
5.18.1 Bavarian Nordic Profile
5.18.2 Bavarian Nordic Main Business
5.18.3 Bavarian Nordic Immuno-oncology Drugs Products, Services and Solutions
5.18.4 Bavarian Nordic Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.18.5 Bavarian Nordic Recent Developments
5.19 Celldex Therapeutics
5.19.1 Celldex Therapeutics Profile
5.19.2 Celldex Therapeutics Main Business
5.19.3 Celldex Therapeutics Immuno-oncology Drugs Products, Services and Solutions
5.19.4 Celldex Therapeutics Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.19.5 Celldex Therapeutics Recent Developments
5.20 ImmunoCellular Therapeutics
5.20.1 ImmunoCellular Therapeutics Profile
5.20.2 ImmunoCellular Therapeutics Main Business
5.20.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Products, Services and Solutions
5.20.4 ImmunoCellular Therapeutics Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.20.5 ImmunoCellular Therapeutics Recent Developments
5.21 Incyte
5.21.1 Incyte Profile
5.21.2 Incyte Main Business
5.21.3 Incyte Immuno-oncology Drugs Products, Services and Solutions
5.21.4 Incyte Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.21.5 Incyte Recent Developments
5.22 Dendreon Corporation
5.22.1 Dendreon Corporation Profile
5.22.2 Dendreon Corporation Main Business
5.22.3 Dendreon Corporation Immuno-oncology Drugs Products, Services and Solutions
5.22.4 Dendreon Corporation Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.22.5 Dendreon Corporation Recent Developments
5.23 Agilent Technologies Inc.
5.23.1 Agilent Technologies Inc. Profile
5.23.2 Agilent Technologies Inc. Main Business
5.23.3 Agilent Technologies Inc. Immuno-oncology Drugs Products, Services and Solutions
5.23.4 Agilent Technologies Inc. Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.23.5 Agilent Technologies Inc. Recent Developments
5.24 Agenus Inc.
5.24.1 Agenus Inc. Profile
5.24.2 Agenus Inc. Main Business
5.24.3 Agenus Inc. Immuno-oncology Drugs Products, Services and Solutions
5.24.4 Agenus Inc. Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.24.5 Agenus Inc. Recent Developments
5.25 Enzo Biochem, Inc.
5.25.1 Enzo Biochem, Inc. Profile
5.25.2 Enzo Biochem, Inc. Main Business
5.25.3 Enzo Biochem, Inc. Immuno-oncology Drugs Products, Services and Solutions
5.25.4 Enzo Biochem, Inc. Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.25.5 Enzo Biochem, Inc. Recent Developments
5.26 Lonza Group
5.26.1 Lonza Group Profile
5.26.2 Lonza Group Main Business
5.26.3 Lonza Group Immuno-oncology Drugs Products, Services and Solutions
5.26.4 Lonza Group Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.26.5 Lonza Group Recent Developments
5.27 Bio-Rad Laboratories, Inc.
5.27.1 Bio-Rad Laboratories, Inc. Profile
5.27.2 Bio-Rad Laboratories, Inc. Main Business
5.27.3 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Products, Services and Solutions
5.27.4 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.27.5 Bio-Rad Laboratories, Inc. Recent Developments
5.28 Avantor, Inc.
5.28.1 Avantor, Inc. Profile
5.28.2 Avantor, Inc. Main Business
5.28.3 Avantor, Inc. Immuno-oncology Drugs Products, Services and Solutions
5.28.4 Avantor, Inc. Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.28.5 Avantor, Inc. Recent Developments
5.29 Spring Bank Pharmaceuticals, Inc.
5.29.1 Spring Bank Pharmaceuticals, Inc. Profile
5.29.2 Spring Bank Pharmaceuticals, Inc. Main Business
5.29.3 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Products, Services and Solutions
5.29.4 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.29.5 Spring Bank Pharmaceuticals, Inc. Recent Developments
5.30 Ferring Pharmaceuticals
5.30.1 Ferring Pharmaceuticals Profile
5.30.2 Ferring Pharmaceuticals Main Business
5.30.3 Ferring Pharmaceuticals Immuno-oncology Drugs Products, Services and Solutions
5.30.4 Ferring Pharmaceuticals Immuno-oncology Drugs Revenue (US$ Million) & (2018-2023)
5.30.5 Ferring Pharmaceuticals Recent Developments
6 North America
6.1 North America Immuno-oncology Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Immuno-oncology Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Immuno-oncology Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Immuno-oncology Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Immuno-oncology Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Immuno-oncology Drugs Market Dynamics
11.1 Immuno-oncology Drugs Industry Trends
11.2 Immuno-oncology Drugs Market Drivers
11.3 Immuno-oncology Drugs Market Challenges
11.4 Immuno-oncology Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
